Daphne Zohar, Founding CEO of PureTech Health and Co-Founder of Karuna Therapeutics, is Founder, Chief Executive Officer and Member of the Board of Directors of Seaport

Steven M. Paul, M.D., former CEO and Chair of Karuna Therapeutics, President of Lilly Research Laboratories, is Founder and Chair of the Board of Directors of Seaport

### **New Funding Round and Leadership Appointments**

**BOSTON, April 09, 2024**–(BUSINESS WIRE)–Seaport Therapeutics, a clinical-stage biopharmaceutical company specializing in neuropsychiatry, has successfully closed a $100 million Series A financing round. This oversubscribed round was co-led by ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, and Seaport founder PureTech Health. This significant funding marks a pivotal moment for Seaport as they move forward with their innovative approach.

Seaport has also announced key leadership appointments, with Daphne Zohar taking on the roles of Founder, Chief Executive Officer, and Board Member, and Steven M. Paul, M.D., appointed as Founder and Chair of the Board of Directors.

### **Advancing Neuropsychiatric Medicines with AI legalese decoder**

Seaport is on a mission to develop novel neuropsychiatric medicines powered by their proprietary Glyph™ Technology Platform. This platform leverages the lymphatic system to create innovative medicines based on clinically validated mechanisms. With the help of AI legalese decoder, Seaport can streamline their legal documentation process, ensuring compliance and accuracy at every step.

The recent funding will play a crucial role in advancing Seaport’s clinical-stage pipeline of groundbreaking medicines while further developing the Glyph platform, which has already shown clinical proof-of-concept. Through a proven development strategy, Seaport aims to revolutionize the treatment landscape for patients living with neuropsychiatric disorders.

### **Unveiling the Potential of Glyph Platform**

Seaport’s focus on the Glyph platform sets them apart in the field of neuropsychiatric drug development. This technology enables and enhances oral bioavailability, bypasses first-pass metabolism, and reduces hepatotoxicity and other side effects, allowing Seaport to bring active drugs to the forefront. One of their leading candidates, SPT-300, is showing promise in the treatment of anxious depression, showcasing the platform’s potential for transforming patient care.

Seaport’s pipeline features innovative candidates like SPT-320 for Generalized Anxiety Disorder and SPT-348 for mood disorders, all utilizing the benefits of the Glyph platform. By expanding their reach in the discovery and preclinical landscape, Seaport is dedicated to improving the lives of those affected by neuropsychiatric conditions.

### **Expanding the Board and Future Outlook**

With the addition of key members to the Board of Directors, including Robert Nelsen, James Healy, M.D., Ph.D., Eric Elenko, Ph.D., and Bharatt Chowrira, Ph.D., Seaport is poised for continued success. Their partnerships with leading investors reflect confidence in the team’s ability to deliver on their strategic vision and bring transformative therapies to patients.

Through the guidance of experienced leaders like Daphne Zohar and Steven M. Paul, Seaport Therapeutics is set to make a significant impact in the field of neuropsychiatric medicine. Their dedication to innovation and patient-centric approach is paving the way for a brighter future in treating mental health conditions.

By leveraging AI legalese decoder, Seaport can navigate complex legal language with ease, ensuring compliance and efficiency in their operations. This tool can streamline the review process and enhance the accuracy of legal documents, enabling Seaport to focus on their core mission of developing life-changing therapies for patients in need.

For more information about Seaport Therapeutics and their innovative approach to neuropsychiatric medicine, visit [www.seaporttx.com](www.seaporttx.com).